Search

In honor of Women's History Month, meet the scientific hero who helped build MSK's molecular biology program.

… Wednesday, March 13, 2019 Ora Rosen Ora Rosen, an expert in insulin signaling, co-founded the Molecular Biology Program at the Sloan Kettering Institute. Ora Rosen Dr. Rosen (right) with graduate students Roman Herrera and Lilli Petruzzelli Summary In honor of Women’s History Month, we’re remembering

Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments.

… Tuesday, December 1, 2009 Summary Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after the disease becomes resistant to standard treatments. Patients with a rare but aggressive form of cancer now have access to a drug that has proven effective after

Jeffrey A. Drebin, MD, PhD, has been named the new Chairman of the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSK). Dr. Drebin brings to MSK decades of experience as a world-class surgical oncologist specializing in pancreaticobiliary, upper gastrointestinal and liver surgery. He joins MSK from the Perelman School of Medicine of the University of Pennsylvania (UPenn) where he was most recently the John Rhea Barton Professor and Chairman of the Department of Surgery. Dr. Drebin formally assumes his new role as Peter Scardino, MD, steps down as Chairman after ten years of visionary leadership.

… Monday, February 27, 2017 VIDEO | 01:36 Meet MSK Surgeon Jeffrey Drebin MSK Surgeon Jeffrey Drebin, Chief Physician Executive, is an expert in pancreatic cancer and treating liver tumors. Learn more about surgery at MSK, which has among the country’s largest cancer surgery departments. Video Details

… Wednesday, March 5, 2025 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce a new community mural, “One Hundred Views,” by artist Naomi Reis. The inaugural MSK mural was created in collaboration with fifth-grade students from  P.S. 183 Robert L. Stevenson Elementary School , the neighboring

In a new study, MSK researchers looked at why glioblastoma brain tumors usually come back after treatment. Their findings suggest that a subset of cells — cancer stem cells — are able to evade current treatments because they are not actively dividing, and that these cells later form new tumors.

… Tuesday, January 11, 2022 Glioblastoma brain tumors are one of the most deadly forms of cancer, with a five-year survival rate of less than 10% for patients 45 and older. Even when the tumors look as if they have been fully removed, they almost always come back. Investigators who are part of Memorial

MSK studies presented at the 2022 American Association for Cancer Research meeting include updates on a targeted therapy for lung cancer, lab research on combining statins with a breast cancer drug, and a new tool for diagnosing blood cancer.

… Monday, April 11, 2022 Dozens of investigators from Memorial Sloan Kettering Cancer Center (MSK) shared their research at the 2022 American Association for Cancer Research (AACR) annual meeting, held April 8 to 13 in New Orleans. The studies presented included: A clinical trial that looked at the long-term

Collaboration will enhance innovation and the adoption of AI in translational research with the goal of improving patient care and outcomes.

… Monday, February 17, 2025 Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN) and Memorial Sloan Kettering Cancer Center (MSK), a leading global cancer center, today announced a collaboration harnessing the power of artificial intelligence (AI), high performance computing (HPC), and

New MSK research identifies a gene mutation associated with resistance to breast cancer treatment; reports encouraging results for expanding use of a new prostate cancer radiotherapy; determines the best radiation level for avoiding complications treating spinal tumors; and finds that proton therapy is effective against previously treated head and neck cancers.

… Tuesday, October 15, 2024 New research from Memorial Sloan Kettering Cancer Center (MSK) identifies a gene mutation associated with resistance to breast cancer treatment, as well as a possible strategy for overcoming the resistance; reports encouraging results for expanding use of a new prostate cancer

New research from MSK offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial appraising two drugs against low- grade glioma; examines MSK’s first-in-the-nation program integrating herbal medicine into oncology care; and identifies how high-grade histologic patterns in lymph node metastases could better predict lung cancer outcomes.

… Thursday, March 9, 2023 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — a hub for basic science and translational research within MSK — offers new proof-of-concept compounds against acute myeloid leukemia; reports results from a phase 1 clinical trial

Learn how to keep your immune system balanced.

… Wednesday, December 22, 2021 You may have read articles or seen products that claim to “boost” your immune system. But what does that mean — and is it even the right goal? Contrary to popular belief, our bodies don’t have one singular immune system. The immune system is actually made up of many different